Potent and selective antagonist of CXCR2 chemokine receptor (IC50=22nM). >150-fold more selective over CXCR1 receptor. Inhibits IL-8- (IC50=8nM) and GROα-mediated (IC50=10nM) calcium mobilisation. Prevents IL-8-induced neutrophil migration. Inhibits HIV replication in lymphocytes and macrophages.
Product Details
| Alternative Name: | N-(2-Bromophenyl)-N’-(2-hydroxy-4-nitrophenyl)urea |
| |
| Formula: | C13H10BrN3O4 |
| |
| MW: | 352.1 |
| |
| CAS: | 182498-32-4 |
| |
| Purity: | ≥98% (HPLC) |
| |
| Identity: | Identity determined by MS, 1H-NMR and 13C-NMR. |
| |
| Appearance: | Yellow solid. |
| |
| Solubility: | Soluble in DMSO (40mg/ml), 100% ethanol or methanol (15mg/ml); slightly soluble in acetonitrile (2mg/ml). |
| |
| Shipping: | Ambient Temperature |
| |
| Long Term Storage: | -20°C |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
CXCR2 antagonists block the N-Ac-PGP-induced neutrophil influx in the airways of mice, but not the production of the chemokine CXCL1: S. Braber, et al.; Eur. J. Pharmacol.
668, 443 (2011),
Abstract;
A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer: B. Wang, et al.; Cancer Res.
66, 3071 (2006),
Abstract;
Full Text
Characterization of the molecular interactions of interleukin-8 (CXCL8), growth related oncogen alpha (CXCL1) and a non-peptide antagonist (SB 225002) with the human CXCR2: J. Catusse, et al.; Biochem. Pharmacol.
65, 813 (2003),
Abstract;
Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration: J.R. White, et al.; J. Biol. Chem.
273, 10095 (1998),
Abstract;
Full Text
